"Alright, let’s break it down—no earth-shattering news here, but the stock’s been flexing some muscle lately. 📈 The 9-period WMA is riding high above the 21-period, signaling short-term bullish energy. RSI’s chilling in the 60s—warm but not overheated. Volume spiked on that May 29th rally, so someone’s betting big. Chart’s messy but holding above key support. No news? No problem—this feels like a stealthy uptrend. BUY on dips and ride the wave. #QuietClimber"

"Whoa, this stock’s got some serious momentum! 🚀 No news to shake things up, but the technicals are doing the talking: 9-period WMA just crossed above the 21-period, and RSI is flirting with overbought (67) but not screaming yet. Volume spiked on the last push—real conviction here. Chart’s got a nice stair-step uptrend. If you’re in, ride the wave; if not, maybe wait for a slight pullback. But hey, FOMO is real—lean BUY. #TrendyStock"

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Marksans Pharma Limited MARKSANS.NS: 176.9 INR

Bullish views